CD8A and cancer: For these Ttx as well as T patients with no concurrent therapy (Tut), and 9 control participants (C) with no evidence of cancer (for methodological details see,5 and a schematic in Figure S1A), the “2x” Ab, CD4+ and CD8+ responses from our previous publication served as benchmark for response waning, and are included in Figure 1A (“2x” non-responders were excluded from the analysis; details on results and statistical parameters are provided in Table S1).